{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:46:34Z","timestamp":1794865594262,"version":"4.9.1"},"reference-count":389,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"China National Science and Technology Major Project for Key New Drug Development","award":["2017ZX09304015"],"award-info":[{"award-number":["2017ZX09304015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01734-x","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:57:14Z","timestamp":1764262634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025)"],"prefix":"10.1186","volume":"18","author":[{"given":"Liling","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"1734_CR1","first-page":"157","volume":"7","author":"W Coley","year":"1896","unstructured":"Coley W. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and bacillus prodigious with a report of 160 cases. Johns Hopkins Hosp Bull. 1896;7:157\u201362.","journal-title":"Johns Hopkins Hosp Bull"},{"key":"1734_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313\u201326.","journal-title":"Cell"},{"key":"1734_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1987","unstructured":"Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily\u2013CTLA-4. Nature. 1987;328:267\u201370.","journal-title":"Nature"},{"key":"1734_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459\u201365.","journal-title":"J Exp Med"},{"key":"1734_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765\u201372.","journal-title":"Int Immunol"},{"key":"1734_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365\u20139.","journal-title":"Nat Med"},{"key":"1734_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"1734_CR8","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1002\/eji.1830241246","volume":"24","author":"B Huard","year":"1994","unstructured":"Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3\/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol. 1994;24:3216\u201321.","journal-title":"Eur J Immunol"},{"key":"1734_CR9","doi-asserted-by":"crossref","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17:54.","DOI":"10.1186\/s13045-024-01581-2"},{"key":"1734_CR10","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727\u201342.","journal-title":"Am J Cancer Res"},{"key":"1734_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trecan.2024.10.009","volume":"11","author":"K Adam","year":"2025","unstructured":"Adam K, Butler SC, Workman CJ, Vignali DAA. Advances in LAG3 cancer immunotherapeutics. Trends Cancer. 2025;11:37\u201348.","journal-title":"Trends Cancer"},{"issue":"8","key":"1734_CR12","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100(8):4712\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1734_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"1734_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"1734_CR15","doi-asserted-by":"crossref","unstructured":"Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, et al. NCCN guidelines\u00ae insights: melanoma: cutaneous, version 2.2024. J Natl Compr Canc Netw. 2024;22:290\u20138.","DOI":"10.6004\/jnccn.2024.0036"},{"key":"1734_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol."},{"key":"1734_CR17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol."},{"key":"1734_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin J, Minor D, D\u2019Angelo S, Neyns B, Smylie M, Miller WH, et al. Overall survival in patients with advanced melanoma who received Nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36:383\u201390.","journal-title":"J Clin Oncol."},{"key":"1734_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","volume":"86","author":"O Hamid","year":"2017","unstructured":"Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017;86:37\u201345.","journal-title":"Eur J Cancer."},{"key":"1734_CR20","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1093\/oncolo\/oyae045","volume":"29","author":"B Tang","year":"2024","unstructured":"Tang B, Duan R, Zhang X, Qin S, Wu D, Chen J, et al. Five-year follow-up of POLARIS-01 phase II trial: Toripalimab as salvage monotherapy in Chinese patients with advanced melanoma. Oncologist. 2024;29:e822\u20137.","journal-title":"Oncologist"},{"key":"1734_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12885-022-10473-y","volume":"23","author":"C Cui","year":"2023","unstructured":"Cui C, Chen Y, Luo Z, Zou Z, Jiang Y, Pan H, et al. Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. BMC Cancer. 2023;23:121.","journal-title":"BMC Cancer"},{"key":"1734_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"1734_CR23","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38:3937\u201346.","journal-title":"J Clin Oncol"},{"key":"1734_CR24","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"1734_CR25","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet"},{"key":"1734_CR26","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.22.01599","volume":"41","author":"C Robert","year":"2023","unstructured":"Robert C, Carlino MS, McNeil C, Ribas A, Grob J-J, Schachter J, et al. Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol. 2023;41:3998\u20134003.","journal-title":"J Clin Oncol"},{"key":"1734_CR27","unstructured":"Junshi biosciences announces the sNDA approval of Toripalimab for the 1st-line treatment of melanoma. 2025. https:\/\/www.biospace.com\/press-releases\/junshi-biosciences-announces-the-snda-approval-of-toripalimab-for-the-1st-line-treatment-of-melanoma."},{"key":"1734_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"1734_CR29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356.","journal-title":"N Engl J Med"},{"key":"1734_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392:11\u201322.","journal-title":"N Engl J Med"},{"key":"1734_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24\u201334.","journal-title":"N Engl J Med"},{"key":"1734_CR32","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835\u201344.","journal-title":"Lancet"},{"key":"1734_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","volume":"24","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet Oncol. 2023;24:33\u201344.","journal-title":"Lancet Oncol"},{"key":"1734_CR34","doi-asserted-by":"crossref","unstructured":"Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020;8. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33361337.","DOI":"10.1136\/jitc-2020-001806"},{"key":"1734_CR35","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, Lebb\u00e9 C, Atkinson V, Mandal\u00e0 M, Nathan PD, Arance A, et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020;26:1557\u201363.","journal-title":"Nat Med"},{"key":"1734_CR36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AMM Eggermont","year":"2015","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol."},{"key":"1734_CR37","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016;375:1845\u201355.","journal-title":"N Engl J Med."},{"key":"1734_CR38","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med."},{"key":"1734_CR39","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465\u201377.","journal-title":"Lancet Oncol."},{"key":"1734_CR40","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med."},{"key":"1734_CR41","doi-asserted-by":"crossref","unstructured":"Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial. Eur J Cancer. 2024;211:114327.","DOI":"10.1016\/j.ejca.2024.114327"},{"key":"1734_CR42","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329.","journal-title":"Lancet."},{"key":"1734_CR43","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.23.02355","volume":"42","author":"JJ Luke","year":"2024","unstructured":"Luke JJ, Ascierto PA, Khattak MA, de la Cruz ML, Del Vecchio M, Rutkowski P, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol. 2024;42:1619\u201324.","journal-title":"J Clin Oncol."},{"key":"1734_CR44","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob J-J, Mohr P, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;29:2835\u201343.","journal-title":"Nat Med."},{"key":"1734_CR45","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391:1696\u2013708.","journal-title":"N Engl J Med"},{"key":"1734_CR46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323.","journal-title":"N Engl J Med"},{"key":"1734_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335.","journal-title":"N Engl J Med."},{"key":"1734_CR48","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med."},{"key":"1734_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723\u201333.","journal-title":"J Clin Oncol."},{"key":"1734_CR50","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350.","journal-title":"Lancet."},{"key":"1734_CR51","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","volume":"16","author":"RS Herbst","year":"2021","unstructured":"Herbst RS, Garon EB, Kim D-W, Cho BC, Gervais R, Perez-Gracia JL, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16:1718\u201332.","journal-title":"J Thorac Oncol."},{"key":"1734_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365.","journal-title":"Lancet"},{"key":"1734_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, et al. Tislelizumab versus docetaxel in patients with\u2002previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial. J Thorac Oncol. 2023;18:93\u2013105.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1734_CR54","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cac2.12385","volume":"42","author":"Y Shi","year":"2022","unstructured":"Shi Y, Wu L, Yu X, et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun (Lond). 2022;42(12):1314\u201330.","journal-title":"Cancer Commun (Lond)."},{"key":"1734_CR55","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"S Lu","year":"2022","unstructured":"Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23:1167\u201379.","journal-title":"Lancet Oncol."},{"key":"1734_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024;332:561\u201370.","journal-title":"JAMA."},{"key":"1734_CR57","doi-asserted-by":"crossref","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cso\u030bszi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823\u201333.","DOI":"10.1056\/NEJMoa1606774"},{"key":"1734_CR58","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50. J Clin Oncol. 2021;39:2339\u201349.","journal-title":"J Clin Oncol."},{"key":"1734_CR59","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet."},{"key":"1734_CR60","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G de Castro","year":"2023","unstructured":"de Castro G, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study. J Clin Oncol. 2023;41:1986\u201391.","journal-title":"J Clin Oncol."},{"key":"1734_CR61","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","volume":"16","author":"J Jassem","year":"2021","unstructured":"Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J Thorac Oncol. 2021;16:1872\u201382.","journal-title":"J Thorac Oncol"},{"key":"1734_CR62","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","volume":"24","author":"M \u00d6zg\u00fcro\u011flu","year":"2023","unstructured":"\u00d6zg\u00fcro\u011flu M, Kilickap S, Sezer A, G\u00fcm\u00fc\u015f M, Bondarenko I, Gogishvili M, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:989\u20131001.","journal-title":"Lancet Oncol."},{"key":"1734_CR63","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. The Lancet. 2025;405:839\u201349.","journal-title":"The Lancet."},{"key":"1734_CR64","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N Engl J Med."},{"key":"1734_CR65","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41:1992\u20138.","journal-title":"J Clin Oncol."},{"key":"1734_CR66","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab- paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung c ancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924\u201337.","journal-title":"Lancet Oncol."},{"key":"1734_CR67","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology program by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15:1636\u201346.","journal-title":"J Thorac Oncol."},{"key":"1734_CR68","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","volume":"171","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. Lung Cancer. 2022;171:56\u201360.","journal-title":"Lung Cancer."},{"key":"1734_CR69","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9:305\u201314.","journal-title":"Lancet Respir Med."},{"key":"1734_CR70","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL phase 3 trial. J Thorac Oncol. 2023;18:628\u201339.","journal-title":"J Thorac Oncol."},{"key":"1734_CR71","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","volume":"16","author":"S Lu","year":"2021","unstructured":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16:1512\u201322.","journal-title":"J Thorac Oncol."},{"key":"1734_CR72","doi-asserted-by":"crossref","unstructured":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Ma Z, et al. Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial). ESMO Open. 2024;9:103728.","DOI":"10.1016\/j.esmoop.2024.103728"},{"key":"1734_CR73","doi-asserted-by":"crossref","unstructured":"Shi Y, Hao Y, Hu Y, Chen C, Chen B, Huang Y, et al. OA05.01 - ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-small Cell Lung Cancer. WCLC 2025.\u00a0https:\/\/cattendee.abstractsonline.com\/meeting\/21151\/presentation\/2490.","DOI":"10.1016\/j.annonc.2025.09.083"},{"key":"1734_CR74","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16:1501\u201311.","journal-title":"J Thorac Oncol."},{"key":"1734_CR75","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709\u201317.","journal-title":"JAMA Oncol."},{"key":"1734_CR76","doi-asserted-by":"crossref","unstructured":"Wang J, Lu S, Yu X, Hu Y, Zhao J, Sun M, et al. Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III rationale-307 trial. ESMO Open. 2024;9:103727.","DOI":"10.1016\/j.esmoop.2024.103727"},{"key":"1734_CR77","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (camel-sq): a phase 3 trial. J Thorac Oncol. 2022;17:544\u201357.","journal-title":"J Thorac Oncol"},{"key":"1734_CR78","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41:1999\u20132006.","journal-title":"J Clin Oncol."},{"key":"1734_CR79","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell. 2024;42:198-208.e3.","journal-title":"Cancer Cell."},{"key":"1734_CR80","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","volume":"12","author":"H Zhong","year":"2024","unstructured":"Zhong H, Sun S, Chen J, Wang Z, Zhao Y, Zhang G, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024;12:355\u201365.","journal-title":"Lancet Respir Med"},{"key":"1734_CR81","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","volume":"23","author":"C Zhou","year":"2022","unstructured":"Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022;23:220\u201333.","journal-title":"Lancet Oncol."},{"key":"1734_CR82","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022;28:2374\u201380.","journal-title":"Nat Med"},{"key":"1734_CR83","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","volume":"18","author":"T Makharadze","year":"2023","unstructured":"Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-lung 3 part 2 trial. J Thorac Oncol. 2023;18:755\u201368.","journal-title":"J Thorac Oncol"},{"key":"1734_CR84","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/JCO.22.00727","volume":"41","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023;41:651\u201363.","journal-title":"J Clin Oncol."},{"key":"1734_CR85","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381:2020\u201331.","journal-title":"N Engl J Med."},{"key":"1734_CR86","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Lee J-S, Ciuleanu T-E, Bernabe Caro R, Nishio M, Urban L, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol. 2023;41:1200\u201312.","journal-title":"J Clin Oncol."},{"key":"1734_CR87","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198\u2013211.","journal-title":"Lancet Oncol"},{"key":"1734_CR88","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.ejca.2024.114296","volume":"211","author":"M Reck","year":"2024","unstructured":"Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, et al. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. Eur J Cancer. 2024;211:114296.","journal-title":"Eur J Cancer"},{"key":"1734_CR89","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III poseidon study. J Clin Oncol. 2023;41:1213\u201327.","journal-title":"J Clin Oncol"},{"key":"1734_CR90","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909\u201324.","journal-title":"J Thorac Oncol."},{"key":"1734_CR91","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41591-025-03658-y","volume":"31","author":"C Zhou","year":"2025","unstructured":"Zhou C, Dong X, Chen G, Wang Z, Wu X, Yao Y, et al. Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial. Nat Med. 2025;31:2375\u201384.","journal-title":"Nat Med."},{"key":"1734_CR92","doi-asserted-by":"crossref","unstructured":"Shi Y, Sun L, Yang R, Huang D, Luo Y, Su H, et al. Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). J Clin Oncol. 2025;43:8514.","DOI":"10.1200\/JCO.2025.43.16_suppl.8514"},{"key":"1734_CR93","doi-asserted-by":"crossref","unstructured":"Socinski MA, Rodriguez Abreu D, Lee DH, Cappuzzo F, Nishio M, Lovly CM, et al. LBA2 skyscraper-06: efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC). Immuno-Oncol Technol. 2024;24:101025.","DOI":"10.1016\/j.iotech.2024.101025"},{"key":"1734_CR94","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301\u201311.","journal-title":"J Clin Oncol."},{"key":"1734_CR95","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23:209\u201319.","journal-title":"Lancet Oncol."},{"key":"1734_CR96","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip E, Altorki N, Zhou C, Valli\u00e8res E, Mart\u00ednez-Mart\u00ed A, Rittmeyer A, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023;34:907\u201319.","journal-title":"Ann Oncol."},{"key":"1734_CR97","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23:1274\u201386.","journal-title":"Lancet Oncol."},{"key":"1734_CR98","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389:1672\u201384.","journal-title":"N Engl J Med."},{"key":"1734_CR99","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 2024;331:201\u201311.","journal-title":"JAMA."},{"key":"1734_CR100","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390:1756\u201369.","journal-title":"N Engl J Med."},{"key":"1734_CR101","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404:1240\u201352.","journal-title":"Lancet"},{"issue":"2","key":"1734_CR102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","volume":"13","author":"D Yue","year":"2025","unstructured":"Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025;13(2):119\u201329.","journal-title":"Lancet Respir Med."},{"key":"1734_CR103","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall survival with neoadjuvant Nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393:741\u201352.","journal-title":"N Engl J Med."},{"key":"1734_CR104","doi-asserted-by":"crossref","unstructured":"Goss G, Darling GE, Westeel V, Nakagawa K, Massuti Sureda B, Perrone F, et al. LBA48 CCTG BR.31: a global, double-blind place bo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35:S1238.","DOI":"10.1016\/j.annonc.2024.08.2289"},{"key":"1734_CR105","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jtho.2024.10.010","volume":"20","author":"WJ Phillips","year":"2025","unstructured":"Phillips WJ, Camidge DR, Wheatley-Price P. Adjuvant immunotherapy should not be used in patients with a pathologic complete response to neoadjuvant chemoimmunotherapy. J Thorac Oncol. 2025;20:30\u20133.","journal-title":"J Thorac Oncol."},{"key":"1734_CR106","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jtho.2024.11.004","volume":"20","author":"D Uprety","year":"2025","unstructured":"Uprety D, Roden AC, Peters S. Adjuvant immunotherapy should be used in patients with non-small cell carcinoma with a pathologic complete response to neoadjuvant immunotherapy. J Thorac Oncol. 2025;20:34\u20138.","journal-title":"J Thorac Oncol."},{"key":"1734_CR107","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","volume":"32","author":"DR Spigel","year":"2021","unstructured":"Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331\u2606. Ann Oncol. 2021;32:631\u201341.","journal-title":"Ann Oncol."},{"key":"1734_CR108","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, Piha-Paul SA, Lopez-Martin J, Atmaca A, Hellmann MD, Schneider JG, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618\u201327.","journal-title":"J Thorac Oncol"},{"key":"1734_CR109","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, et al. Third-Line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237\u201344.","journal-title":"J Thorac Oncol."},{"key":"1734_CR110","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38:2369\u201379.","journal-title":"J Clin Oncol."},{"key":"1734_CR111","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"1734_CR112","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339.","journal-title":"Lancet"},{"key":"1734_CR113","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739\u201347.","journal-title":"Lancet Oncol"},{"key":"1734_CR114","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328:1223\u201332.","journal-title":"JAMA"},{"key":"1734_CR115","first-page":"e245019","volume":"11","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Zhang W, Wu L, Zhou C, Wang D, Xia B, et al. Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial. JAMA Oncol. 2024;11:e245019.","journal-title":"JAMA Oncol"},{"key":"1734_CR116","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","volume":"19","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024;19:1073\u201385.","journal-title":"J Thorac Oncol"},{"key":"1734_CR117","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","volume":"30","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med. 2024;30:2967\u201376.","journal-title":"Nat Med"},{"key":"1734_CR118","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391:1313\u201327.","journal-title":"N Engl J Med"},{"key":"1734_CR119","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","volume":"34","author":"LQM Chow","year":"2016","unstructured":"Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34:3838\u201345.","journal-title":"J Clin Oncol."},{"key":"1734_CR120","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156\u201367.","journal-title":"Lancet."},{"key":"1734_CR121","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"1734_CR122","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"1734_CR123","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1038\/s41591-024-03110-7","volume":"30","author":"Y Shi","year":"2024","unstructured":"Shi Y, Guo W, Wang W, Wu Y, Fang M, Huang X, et al. Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial. Nat Med. 2024;30:2568\u201375.","journal-title":"Nat Med"},{"key":"1734_CR124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2","volume":"43","author":"J Bourhis","year":"2025","unstructured":"Bourhis J, Auperin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, et al. Nivopostop (GORTEC 2018\u201301): a phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. J Clin Oncol. 2025;43: LBA2\u2013LBA2.","journal-title":"J Clin Oncol"},{"key":"1734_CR125","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"F-H Wang","year":"2021","unstructured":"Wang F-H, Wei X-L, Feng J, Li Q, Xu N, Hu X-C, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39:704\u201312.","journal-title":"J Clin Oncol."},{"key":"1734_CR126","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003790","volume":"9","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhou T, Chen X, Li J, Pan J, He X, et al. Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9: e003790.","journal-title":"J Immunother Cancer"},{"key":"1734_CR127","doi-asserted-by":"crossref","unstructured":"Shi Y, Qin X, Peng X, Zeng A, Li J, Chen C, et al. Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study. Lancet Reg Health. 2023;31:100617.","DOI":"10.1016\/j.lanwpc.2022.100617"},{"key":"1734_CR128","doi-asserted-by":"crossref","unstructured":"Chen X, Wang W, Zou Q, Zhu X, Lin Q, Jiang Y, et al. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study. Signal Transduct Target Ther. 2024;9:148.","DOI":"10.1038\/s41392-024-01865-6"},{"key":"1734_CR129","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27:1536\u201343.","journal-title":"Nat Med"},{"key":"1734_CR130","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J, Hu C, Xu M, Li W, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22:1162\u201374.","journal-title":"Lancet Oncol"},{"key":"1734_CR131","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, et al. Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell. 2023;41:1061-1072.e4.","journal-title":"Cancer Cell"},{"key":"1734_CR132","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT011","volume":"85","author":"C Hu","year":"2025","unstructured":"Hu C, Chen X, Xu T, Huang S, Liu F, Qu S, et al. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a global, multicenter, randomized, double-blind, phase 3 trial (AK105-304). Cancer Res. 2025;85: CT011.","journal-title":"Cancer Res"},{"key":"1734_CR133","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1200\/JCO.2025.43.16_suppl.6004","volume":"43","author":"Y Shi","year":"2025","unstructured":"Shi Y, Mai H, Chen C, Wang Y, Li J, Jin H, et al. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R\/M NPC): results from a randomized, double-blind, phase 3 study. J Clin Oncol. 2025;43:6004\u20136004.","journal-title":"J Clin Oncol"},{"key":"1734_CR134","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin C-Y, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317.","journal-title":"Lancet Oncol."},{"key":"1734_CR135","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38:4138\u201348.","journal-title":"J Clin Oncol"},{"key":"1734_CR136","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21:832\u201342.","journal-title":"Lancet Oncol."},{"key":"1734_CR137","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326:916\u201325.","journal-title":"JAMA."},{"key":"1734_CR138","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022;386:449\u201362.","journal-title":"N Engl J Med."},{"key":"1734_CR139","doi-asserted-by":"crossref","unstructured":"Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714.","DOI":"10.1136\/bmj-2021-068714"},{"key":"1734_CR140","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"Z-X Wang","year":"2022","unstructured":"Wang Z-X, Cui C, Yao J, Zhang Y, Li M, Feng J, et al. Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40:277\u2013288.e3.","journal-title":"Cancer Cell."},{"key":"1734_CR141","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24:483\u201395.","journal-title":"Lancet Oncol"},{"key":"1734_CR142","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","volume":"29","author":"Y Song","year":"2023","unstructured":"Song Y, Zhang B, Xin D, Kou X, Tan Z, Zhang S, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023;29:473\u201382.","journal-title":"Nat Med."},{"key":"1734_CR143","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41591-024-02797-y","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Chen Z, Bai Y, Liu B, Li Q, Zhang J, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nat Med. 2024;30:740\u20138.","journal-title":"Nat Med."},{"key":"1734_CR144","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371.","journal-title":"Lancet"},{"key":"1734_CR145","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203.","journal-title":"N Engl J Med"},{"key":"1734_CR146","doi-asserted-by":"crossref","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4:e180013.","DOI":"10.1001\/jamaoncol.2018.0013"},{"key":"1734_CR147","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang Y-J, Fuchs C, Wyrwicz L, Lee K-W, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1571\u201380.","journal-title":"JAMA Oncol."},{"key":"1734_CR148","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol. 2024;42:2012\u201320.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1734_CR149","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"2","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;2(4):1181\u201395.","journal-title":"Lancet Oncol."},{"key":"1734_CR150","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330:2064\u201374.","journal-title":"JAMA."},{"key":"1734_CR151","doi-asserted-by":"crossref","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","DOI":"10.1136\/bmj-2023-078876"},{"key":"1734_CR152","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.2024.28463","volume":"333","author":"X Zhang","year":"2025","unstructured":"Zhang X, Wang J, Wang G, Zhang Y, Fan Q, Lu C, et al. First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial. JAMA. 2025;333:1305\u201314.","journal-title":"JAMA."},{"key":"1734_CR153","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31:1163\u201370.","journal-title":"Nat Med"},{"key":"1734_CR154","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208.","journal-title":"Lancet"},{"key":"1734_CR155","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1734_CR156","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol."},{"key":"1734_CR157","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz H-J, Gelsomino F, Aglietta M, et al. Durable clinical benefit with Nivolumab Plus Ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic Colorectal Cancer. J Clin Oncol. 2018;36:773\u20139.","journal-title":"J Clin Oncol."},{"key":"1734_CR158","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, Geva R, J\u00e4ger D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11\u20139.","journal-title":"J Clin Oncol."},{"key":"1734_CR159","doi-asserted-by":"crossref","unstructured":"Andre\u0301 T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colore ctal cancer. N Engl J Med. 2020;383:2207\u201318.","DOI":"10.1056\/NEJMoa2017699"},{"key":"1734_CR160","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz","year":"2022","unstructured":"Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659\u201370.","journal-title":"Lancet Oncol"},{"key":"1734_CR161","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391:2014\u201326.","journal-title":"N Engl J Med"},{"key":"1734_CR162","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","volume":"405","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Elez E, Lenz HJ, Jensen LH, Touchefeu Y, Van Cutsem E, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405:383\u201395.","journal-title":"Lancet"},{"key":"1734_CR163","doi-asserted-by":"publisher","first-page":"LBA1\u2013LBA1","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1","volume":"43","author":"FA Sinicrope","year":"2025","unstructured":"Sinicrope FA, Ou FS, Arnold D, Peters W, Behrens RJ, Lieu CH, et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). J Clin Oncol. 2025;43:LBA1\u2013LBA1.","journal-title":"J Clin Oncol"},{"key":"1734_CR164","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim S-B, Ajani JA, Zhao K, He Z, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40:3065\u201376.","journal-title":"J Clin Oncol"},{"key":"1734_CR165","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"1734_CR166","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42:1830\u201350.","journal-title":"J Clin Oncol."},{"key":"1734_CR167","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.","DOI":"10.1056\/EVIDoa2100070"},{"key":"1734_CR168","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35:448\u201357.","journal-title":"Ann Oncol."},{"key":"1734_CR169","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023;9:1651\u20139.","journal-title":"JAMA Oncol."},{"key":"1734_CR170","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet."},{"key":"1734_CR171","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77\u201390.","journal-title":"Lancet Oncol"},{"key":"1734_CR172","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1734_CR173","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"1734_CR174","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22:977\u201390.","journal-title":"Lancet Oncol"},{"key":"1734_CR175","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresecta ble hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133\u201346.","journal-title":"Lancet."},{"key":"1734_CR176","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-24-0006","volume":"30","author":"Y Chen","year":"2024","unstructured":"Chen Y, Du C, Shen S, Zhang W, Shan Y, Lyu A, et al. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: a prospective, multicenter, single-arm, phase II trial. Clin Cancer Res. 2024;30:2937\u201344.","journal-title":"Clin Cancer Res"},{"key":"1734_CR177","doi-asserted-by":"crossref","unstructured":"Xu J, Zhang Y, Wang G, Chen W, Zhuang L, Gu S, et al. SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: a randomized phase 3 trial. J Clin Oncol. 2024;42:4092.","DOI":"10.1200\/JCO.2024.42.16_suppl.4092"},{"key":"1734_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00403-9","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9.","journal-title":"Lancet"},{"key":"1734_CR179","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147:2190\u20138.","journal-title":"Int J Cancer"},{"key":"1734_CR180","doi-asserted-by":"crossref","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1:EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"1734_CR181","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, He AR, Bouattour M, Okusaka T, Qin S, Chen L-T, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participa nts with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1734_CR182","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compare d with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet."},{"key":"1734_CR183","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1200\/JCO.22.00620","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial. J Clin Oncol. 2023;41:1434\u201343.","journal-title":"J Clin Oncol."},{"key":"1734_CR184","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u201352.","journal-title":"Lancet Oncol."},{"key":"1734_CR185","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193\u2013202.","journal-title":"J Clin Oncol."},{"key":"1734_CR186","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000527175","volume":"12","author":"Z Ren","year":"2023","unstructured":"Ren Z, Ducreux M, Abou-Alfa GK, Merle P, Fang W, Edeline J, et al. Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial. Liver Cancer. 2023;12:72\u201384.","journal-title":"Liver Cancer"},{"key":"1734_CR187","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21:571\u201380.","journal-title":"Lancet Oncol"},{"key":"1734_CR188","doi-asserted-by":"crossref","unstructured":"Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564.","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"1734_CR189","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116\u201327.","journal-title":"N Engl J Med."},{"key":"1734_CR190","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563\u201373.","journal-title":"Lancet Oncol."},{"key":"1734_CR191","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103\u201315.","journal-title":"N Engl J Med."},{"key":"1734_CR192","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","volume":"36","author":"TK Choueiri","year":"2025","unstructured":"Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, et al. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN renal 101 trial. Ann Oncol. 2025;36:387\u201392.","journal-title":"Ann Oncol."},{"key":"1734_CR193","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829\u201341.","journal-title":"N Engl J Med."},{"key":"1734_CR194","doi-asserted-by":"crossref","unstructured":"Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 2024;9:102994.","DOI":"10.1016\/j.esmoop.2024.102994"},{"key":"1734_CR195","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289\u2013300.","journal-title":"N Engl J Med."},{"key":"1734_CR196","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Porta C, Eto M, Powles T, Gr\u00fcnwald V, Hutson TE, et al. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. 2024;42:1222\u20138.","journal-title":"J Clin Oncol."},{"key":"1734_CR197","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","volume":"35","author":"XQ Yan","year":"2024","unstructured":"Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2024;35:190\u20139.","journal-title":"Ann Oncol."},{"key":"1734_CR198","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475\u201385.","journal-title":"Exp Mol Med"},{"key":"1734_CR199","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683\u201394.","journal-title":"N Engl J Med"},{"key":"1734_CR200","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","volume":"23","author":"T Powles","year":"2022","unstructured":"Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:1133\u201344.","journal-title":"Lancet Oncol"},{"key":"1734_CR201","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","volume":"400","author":"SK Pal","year":"2022","unstructured":"Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400:1103\u201316.","journal-title":"Lancet"},{"key":"1734_CR202","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","volume":"401","author":"RJ Motzer","year":"2023","unstructured":"Motzer RJ, Russo P, Gr\u00fcnwald V, Tomita Y, Zurawski B, Parikh O, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023;401:821\u201332.","journal-title":"Lancet."},{"key":"1734_CR203","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","volume":"25","author":"ME Allaf","year":"2024","unstructured":"Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25:1038\u201352.","journal-title":"Lancet Oncol."},{"key":"1734_CR204","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312\u201322.","journal-title":"Lancet Oncol"},{"key":"1734_CR205","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"1734_CR206","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34:289\u201399.","journal-title":"Ann Oncol"},{"key":"1734_CR207","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19:51\u201364.","journal-title":"Lancet Oncol."},{"key":"1734_CR208","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","volume":"112","author":"D Ye","year":"2021","unstructured":"Ye D, Liu J, Zhou A, Zou Q, Li H, Fu C, et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 2021;112:305\u201313.","journal-title":"Cancer Sci"},{"key":"1734_CR209","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-21-2210","volume":"28","author":"X Sheng","year":"2022","unstructured":"Sheng X, Chen H, Hu B, Yao X, Liu Z, Yao X, et al. Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03. Clin Cancer Res. 2022;28:489\u201397.","journal-title":"Clin Cancer Res."},{"key":"1734_CR210","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet."},{"key":"1734_CR211","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016;34:3119\u201325.","journal-title":"J Clin Oncol."},{"key":"1734_CR212","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1574\u201388.","journal-title":"Lancet Oncol."},{"key":"1734_CR213","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67\u201376.","journal-title":"Lancet."},{"key":"1734_CR214","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1547\u201357.","journal-title":"Lancet"},{"key":"1734_CR215","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778\u201389.","journal-title":"N Engl J Med."},{"key":"1734_CR216","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388.","journal-title":"N Engl J Med"},{"key":"1734_CR217","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330.","journal-title":"N Engl J Med"},{"key":"1734_CR218","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ull\u00e9n A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up. J Clin Oncol. 2023;41:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"1734_CR219","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919\u201330.","journal-title":"Lancet Oncol"},{"key":"1734_CR220","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi A, Roumigui\u00e9 M, Kamat AM, Shore ND, Boormans JL, Esen AA, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024;25:720\u201330.","journal-title":"Lancet Oncol"},{"key":"1734_CR221","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024). J Urol. 2024;212:3\u201310.","journal-title":"J Urol"},{"key":"1734_CR222","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384:2102\u201314.","journal-title":"N Engl J Med"},{"key":"1734_CR223","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol. 2025;43:15\u201321.","journal-title":"J Clin Oncol"},{"key":"1734_CR224","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392:45\u201355.","journal-title":"N Engl J Med"},{"key":"1734_CR225","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391:1773\u201386.","journal-title":"N Engl J Med"},{"key":"1734_CR226","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"1734_CR227","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126:4156\u201367.","journal-title":"Cancer"},{"key":"1734_CR228","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"1734_CR229","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir NM, Albig\u00e8s L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024;35:1026\u201338.","journal-title":"Ann Oncol."},{"key":"1734_CR230","doi-asserted-by":"crossref","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:331\u201357.","DOI":"10.6004\/jnccn.2024.0035"},{"key":"1734_CR231","doi-asserted-by":"crossref","unstructured":"El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, et al. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021;7:150.","DOI":"10.1038\/s41523-021-00346-1"},{"key":"1734_CR232","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1734_CR233","doi-asserted-by":"crossref","unstructured":"Heater NK, Warrior S, Lu J. Current and future immunotherapy for breast cancer. J Hematol Oncol. 2024;17:131.","DOI":"10.1186\/s13045-024-01649-z"},{"key":"1734_CR234","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a random ised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet."},{"key":"1734_CR235","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326.","journal-title":"N Engl J Med."},{"key":"1734_CR236","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024;30:249\u201356.","journal-title":"Nat Med."},{"key":"1734_CR237","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med."},{"key":"1734_CR238","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH, Di\u00e9ras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32:983\u201393.","journal-title":"Ann Oncol."},{"key":"1734_CR239","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"1734_CR240","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405\u201311.","journal-title":"Ann Oncol."},{"key":"1734_CR241","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397\u2013404.","journal-title":"Ann Oncol."},{"key":"1734_CR242","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499\u2013511.","journal-title":"Lancet Oncol"},{"key":"1734_CR243","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med."},{"key":"1734_CR244","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556\u201367.","journal-title":"N Engl J Med."},{"key":"1734_CR245","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981\u201391.","journal-title":"N Engl J Med."},{"key":"1734_CR246","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1734_CR247","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of Pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470\u20138.","journal-title":"J Clin Oncol"},{"key":"1734_CR248","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-22-1280","volume":"28","author":"J An","year":"2022","unstructured":"An J, Tang J, Li BX, Xiong H, Qiu H, Luo L, et al. Efficacy and safety of the anti-PD-L1 mAb Socazolimab for recurrent or metastatic cervical cancer: a phase i dose-escalation and expansion study. Clin Cancer Res. 2022;28:5098\u2013106.","journal-title":"Clin Cancer Res."},{"key":"1734_CR249","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1136\/ijgc-2023-004705","volume":"33","author":"L Xia","year":"2023","unstructured":"Xia L, Wang J, Wang C, Zhang Q, Zhu J, Rao Q, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. Int J Gynecol Cancer. 2023;33:1861\u20138.","journal-title":"Int J Gynecol Cancer."},{"key":"1734_CR250","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ygyno.2024.10.001","volume":"191","author":"G Li","year":"2024","unstructured":"Li G, Li X, Yin R, Feng M, Zuo J, Wei S, et al. Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent\/metastatic cervical cancer. Gynecol Oncol. 2024;191:165\u201371.","journal-title":"Gynecol Oncol."},{"key":"1734_CR251","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","volume":"24","author":"X Gao","year":"2023","unstructured":"Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, et al. Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial. Lancet Oncol. 2023;24:1134\u201346.","journal-title":"Lancet Oncol."},{"key":"1734_CR252","first-page":"A5","volume":"34","author":"H Lou","year":"2024","unstructured":"Lou H, Zhou Y, Li D, Zhang H, Zhang M, Wang L, et al. 251 Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase 2 clinical trial (DUBHE-C-206). Int J Gynecol Cancer. 2024;34:A5.","journal-title":"Int J Gynecol Cancer"},{"key":"1734_CR253","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40265-025-02160-6","volume":"85","author":"SJ Keam","year":"2025","unstructured":"Keam SJ. Iparomlimab and Tuvonralimab: First Approval. Drugs. 2025;85:699\u2013706.","journal-title":"Drugs."},{"key":"1734_CR254","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385:1856\u201367.","journal-title":"N Engl J Med"},{"key":"1734_CR255","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","volume":"41","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol. 2023;41:5505\u201311.","journal-title":"J Clin Oncol"},{"key":"1734_CR256","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403:1341\u201350.","journal-title":"Lancet"},{"key":"1734_CR257","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404:1321\u201332.","journal-title":"Lancet"},{"key":"1734_CR258","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","volume":"404","author":"X Wu","year":"2024","unstructured":"Wu X, Sun Y, Yang H, Wang J, Lou H, Li D, et al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet. 2024;404:1668\u201376.","journal-title":"Lancet"},{"key":"1734_CR259","doi-asserted-by":"publisher","first-page":"S1544","DOI":"10.1016\/j.annonc.2024.10.394","volume":"35","author":"N Liu","year":"2024","unstructured":"Liu N, Yang Z, Tang D, Lou H, Zhang K, Cao H, et al. 373O First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) \u00b1 bevacizumab (BEV) for recurrent or metastatic cervical cancer (r\/mCC): updated results of the phase II DUBHE-C-204 study. Ann Oncol. 2024;35:S1544.","journal-title":"Ann Oncol"},{"key":"1734_CR260","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","volume":"6","author":"A Oaknin","year":"2020","unstructured":"Oaknin A, Tinker AV, Gilbert L, Samou\u00eblian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody Dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6:1766\u201372.","journal-title":"JAMA Oncol"},{"key":"1734_CR261","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","volume":"29","author":"A Oaknin","year":"2023","unstructured":"Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S, et al. Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res. 2023;29:4564\u201374.","journal-title":"Clin Cancer Res"},{"key":"1734_CR262","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.21.01874","volume":"40","author":"DM O\u2019Malley","year":"2022","unstructured":"O\u2019Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus AA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40:752\u201361.","journal-title":"J Clin Oncol"},{"key":"1734_CR263","doi-asserted-by":"publisher","first-page":"11448","DOI":"10.3390\/ijms252111448","volume":"25","author":"V Tuninetti","year":"2024","unstructured":"Tuninetti V, Farolfi A, Rognone C, Montanari D, De Giorgi U, Valabrega G. Treatment strategies for advanced endometrial cancer according to molecular classification. Int J Mol Sci. 2024;25:11448.","journal-title":"Int J Mol Sci"},{"key":"1734_CR264","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386:437\u201348.","journal-title":"N Engl J Med."},{"key":"1734_CR265","doi-asserted-by":"crossref","unstructured":"Wu X, Chen X, Luo X, Wang K, Wang D, An R, et al. LB011\/#1557 Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQ B2450-II-08. Int J Gynecol Cancer. 2024;34:A6.","DOI":"10.1136\/ijgc-2024-IGCS.6"},{"key":"1734_CR266","doi-asserted-by":"crossref","unstructured":"Wu X, Wang J, Wang D, Li G, Zhang J, Chen H, et al. Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: results from a multicenter, single-arm phase 2 study. J Clin Oncol. 2024;42:5619.","DOI":"10.1200\/JCO.2024.42.16_suppl.5619"},{"key":"1734_CR267","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov\u00e1k Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145\u201358.","journal-title":"N Engl J Med."},{"key":"1734_CR268","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","volume":"35","author":"MA Powell","year":"2024","unstructured":"Powell MA, Bj\u00f8rge L, Willmott L, Nov\u00e1k Z, Black D, Gilbert L, et al. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial. Ann Oncol. 2024;35:728\u201338.","journal-title":"Ann Oncol."},{"key":"1734_CR269","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","volume":"388","author":"RN Eskander","year":"2023","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023;388:2159\u201370.","journal-title":"N Engl J Med."},{"key":"1734_CR270","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","volume":"31","author":"RN Eskander","year":"2025","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025;31:1539\u201346.","journal-title":"Nat Med."},{"key":"1734_CR271","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1200\/JCO.23.02132","volume":"42","author":"SN Westin","year":"2024","unstructured":"Westin SN, Moore K, Chon HS, Lee J-Y, Thomes Pepin J, Sundborg M, et al. Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024;42:283\u201399.","journal-title":"J Clin Oncol"},{"key":"1734_CR272","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med."},{"key":"1734_CR273","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283\u201394.","journal-title":"Lancet Oncol."},{"issue":"5","key":"1734_CR274","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","volume":"22","author":"YL Kasamon","year":"2017","unstructured":"Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. Oncologist. 2017;22(5):585\u201391.","journal-title":"Oncologist."},{"key":"1734_CR275","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134:1144\u201353.","journal-title":"Blood."},{"key":"1734_CR276","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood.2022019386","volume":"142","author":"P Armand","year":"2023","unstructured":"Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma. Blood. 2023;142:878\u201386.","journal-title":"Blood."},{"key":"1734_CR277","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22:512\u201324.","journal-title":"Lancet Oncol."},{"key":"1734_CR278","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6:e12-9.","journal-title":"Lancet Haematol."},{"key":"1734_CR279","doi-asserted-by":"crossref","unstructured":"Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, et al. Sintilimab for relapsed\/refractory classical Hodgkin\u2019s lymphoma: long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study. J Clin Oncol. 2020;38:8034.","DOI":"10.1200\/JCO.2020.38.15_suppl.8034"},{"key":"1734_CR280","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A single-arm, multicenter, phase II study of Camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 2019;25:7363\u20139.","journal-title":"Clin Cancer Res."},{"key":"1734_CR281","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ijc.33852","volume":"150","author":"J Wu","year":"2022","unstructured":"Wu J, Song Y, Chen X, Lin T, Cao J, Liu Y, et al. Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended follow-up of the multicenter, single-arm, phase 2 study. Int J Cancer. 2022;150:984\u201392.","journal-title":"Int J Cancer."},{"key":"1734_CR282","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","volume":"34","author":"Y Song","year":"2020","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020;34:533\u201342.","journal-title":"Leukemia."},{"key":"1734_CR283","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","volume":"28","author":"Y Song","year":"2022","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, et al. Tislelizumab for relapsed\/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis. Clin Cancer Res. 2022;28:1147\u201356.","journal-title":"Clin Cancer Res."},{"key":"1734_CR284","doi-asserted-by":"crossref","unstructured":"Song Y, Zhou K, Jin C, Qian Z, Hou M, Fan L, et al. Penpulimab for relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, pivotal phase I\/II trial (AK105-201). Front Oncol. 2022;12:925236.","DOI":"10.3389\/fonc.2022.925236"},{"key":"1734_CR285","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2021.07.021","volume":"164","author":"N Lin","year":"2022","unstructured":"Lin N, Zhang M, Bai H, Liu H, Cui J, Ke X, et al. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter, single-arm, phase II study. Eur J Cancer. 2022;164:117\u201326.","journal-title":"Eur J Cancer."},{"key":"1734_CR286","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-16-1387","volume":"23","author":"SM Ansell","year":"2017","unstructured":"Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res. 2017;23:1623\u20136.","journal-title":"Clin Cancer Res."},{"key":"1734_CR287","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131:68\u201383.","journal-title":"Blood."},{"key":"1734_CR288","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-24-0942","volume":"30","author":"M Pourmaleki","year":"2024","unstructured":"Pourmaleki M, Jones CJ, Mellinghoff SD, Greenstein BD, Kumar P, Foronda M, et al. Multiplexed spatial profiling of Hodgkin Reed-Sternberg cell neighborhoods in classic Hodgkin lymphoma. Clin Cancer Res. 2024;30:3881\u201393.","journal-title":"Clin Cancer Res"},{"key":"1734_CR289","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med. 2024;391:1379\u201389.","journal-title":"N Engl J Med"},{"key":"1734_CR290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2023-181467","volume":"142","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood. 2023;142:141\u20135.","journal-title":"Blood."},{"key":"1734_CR291","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.02367","volume":"41","author":"H Huang","year":"2023","unstructured":"Huang H, Tao R, Hao S, Yang Y, Cen H, Zhou H, et al. Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study. J Clin Oncol. 2023;41:3032\u201341.","journal-title":"J Clin Oncol."},{"key":"1734_CR292","doi-asserted-by":"crossref","unstructured":"Chen X, Qin Y, Xue X, Xie Z, Xie T, Huang L, et al. Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Immunol Immunother. 2024;73(12):250.","DOI":"10.1007\/s00262-024-03840-0"},{"key":"1734_CR293","doi-asserted-by":"crossref","unstructured":"Shi Y, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021;14:12.","DOI":"10.1186\/s13045-021-01033-1"},{"key":"1734_CR294","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1158\/1078-0432.CCR-20-2819","volume":"26","author":"Y Shi","year":"2020","unstructured":"Shi Y, Cai Q, Jiang Y, Huang G, Bi M, Wang B, et al. Activity and safety of geptanolimab (GB226) for patients with unresectable, recurrent, or metastatic alveolar soft part sarcoma: a phase II, single-arm study. Clin Cancer Res. 2020;26:6445\u201352.","journal-title":"Clin Cancer Res."},{"key":"1734_CR295","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s00262-023-03467-7","volume":"72","author":"Y Shi","year":"2023","unstructured":"Shi Y, Cui J, Zhou H, Zhang X, Zou L, Cao J, et al. Efficacy and safety of geptanolimab (GB226) for relapsed\/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003). Cancer Immunol Immunother. 2023;72:2991\u20133002.","journal-title":"Cancer Immunol Immunother."},{"key":"1734_CR296","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"1734_CR297","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33:488\u201399.","journal-title":"Ann Oncol"},{"key":"1734_CR298","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:2295\u2013306.","journal-title":"Lancet"},{"key":"1734_CR299","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","volume":"21","author":"MR Migden","year":"2020","unstructured":"Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21:294\u2013305.","journal-title":"Lancet Oncol"},{"key":"1734_CR300","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000775","volume":"8","author":"D Rischin","year":"2020","unstructured":"Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8: e000775.","journal-title":"J Immunother Cancer"},{"key":"1734_CR301","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","volume":"92","author":"BGM Hughes","year":"2025","unstructured":"Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, et al. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol. 2025;92:68\u201377.","journal-title":"J Am Acad Dermatol"},{"key":"1734_CR302","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","volume":"32","author":"BGM Hughes","year":"2021","unstructured":"Hughes BGM, Munoz-Couselo E, Mortier L, Bratland \u00c5, Gutzmer R, Roshdy O, et al. Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32:1276\u201385.","journal-title":"Ann Oncol"},{"key":"1734_CR303","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007637","volume":"11","author":"P Clingan","year":"2023","unstructured":"Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023;11: e007637.","journal-title":"J Immunother Cancer"},{"key":"1734_CR304","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.annonc.2023.10.123","volume":"35","author":"KD Lewis","year":"2024","unstructured":"Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024;35:221\u20138.","journal-title":"Ann Oncol"},{"key":"1734_CR305","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374\u201385.","journal-title":"Lancet Oncol"},{"key":"1734_CR306","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542\u201352.","journal-title":"N Engl J Med"},{"key":"1734_CR307","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37:693\u2013702.","journal-title":"J Clin Oncol"},{"key":"1734_CR308","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40257-024-00885-w","volume":"25","author":"L Mortier","year":"2024","unstructured":"Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, et al. Pembrolizumab for the first-line treatment of recurrent locally advanced or metastatic merkel cell carcinoma: results from the single-arm, open-label, phase III KEYNOTE-913 study. Am J Clin Dermatol. 2024;25:987\u201396.","journal-title":"Am J Clin Dermatol"},{"key":"1734_CR309","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen AP, Sharon E, O\u2019Sullivan-Coyne G, Moore N, Foster JC, Hu JS, et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med. 2023;389:911\u201321.","journal-title":"N Engl J Med"},{"key":"1734_CR310","unstructured":"DailyMed - KEYTRUDA- pembrolizumab injection, powder, lyophilized, for solution KEYTRUDA- pembrolizumab injection, solution. Available from: https:\/\/www.dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287#. Cited 2025 May 11."},{"key":"1734_CR311","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"1734_CR312","doi-asserted-by":"publisher","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","volume":"6","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Berton D, Curigliano G, Sabatier R, Tinker AV, Oaknin A, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open. 2023;6:e2341165\u2013e2341165.","journal-title":"JAMA Netw Open"},{"key":"1734_CR313","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14:95.","journal-title":"J Hematol Oncol"},{"key":"1734_CR314","doi-asserted-by":"publisher","first-page":"257","DOI":"10.21147\/j.issn.1000-9604.2024.03.03","volume":"36","author":"J Li","year":"2024","unstructured":"Li J, Xu Y, Zang A, Gao Y, Gao Q, Zhang Y, et al. Tislelizumab in previously treated, locally advanced unresectable\/metastatic microsatellite instability-high\/mismatch repair-deficient solid tumors. Chin J Cancer Res. 2024;36:257\u201369.","journal-title":"Chin J Cancer Res"},{"key":"1734_CR315","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41416-022-02001-3","volume":"127","author":"S Qin","year":"2022","unstructured":"Qin S, Li J, Zhong H, Jin C, Chen L, Yuan X, et al. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. Br J Cancer. 2022;127:2241\u20138.","journal-title":"Br J Cancer"},{"key":"1734_CR316","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101301","volume":"4","author":"B Zhang","year":"2023","unstructured":"Zhang B, Song Y, Luo S, Yin X, Li E, Wang H, et al. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: a multicenter phase 2 study. Cell Rep Med. 2023;4: 101301.","journal-title":"Cell Rep Med"},{"key":"1734_CR317","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104768","volume":"212","author":"M-T Melissari","year":"2025","unstructured":"Melissari M-T, Papatheodoridi A, Argyriadis A, Kaparelou M, Dimopoulos MA, Zagouri F. Immunotherapy in primary hormone-receptor positive breast cancer: a systematic review. Crit Rev Oncol Hematol. 2025;212: 104768.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1734_CR318","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395\u2013405.","journal-title":"J Clin Oncol"},{"key":"1734_CR319","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMc1510353","volume":"373","author":"Y Asaoka","year":"2015","unstructured":"Asaoka Y, Ijichi H, Koike K. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373:1979.","journal-title":"N Engl J Med"},{"key":"1734_CR320","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/curroncol31070283","volume":"31","author":"B Garlisi","year":"2024","unstructured":"Garlisi B, Lauks S, Aitken C, Ogilvie LM, Lockington C, Petrik D, et al. The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities. Curr Oncol. 2024;31:3826\u201344.","journal-title":"Curr Oncol"},{"key":"1734_CR321","doi-asserted-by":"crossref","unstructured":"von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S, et al. Immunotherapy in advanced prostate cancer-light at the end of the tunnel? Int J Mol Sci. 2022;23:2569.","DOI":"10.3390\/ijms23052569"},{"key":"1734_CR322","doi-asserted-by":"crossref","unstructured":"Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.","DOI":"10.1038\/s41467-023-36325-2"},{"key":"1734_CR323","doi-asserted-by":"crossref","unstructured":"Kwon WA, Joung JY. Immunotherapy in prostate cancer: from a \u201cCold\u201d Tumor to a \u201cHot\u201d prospect. Cancers (Basel). 2025;17:AQ121064.","DOI":"10.3390\/cancers17071064"},{"key":"1734_CR324","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-21-4413","volume":"28","author":"J Fucikova","year":"2022","unstructured":"Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, et al. An autologous dendritic cell vaccine promotes anticancer immunity in patients with ovarian cancer with low mutational burden and cold tumors. Clin Cancer Res. 2022;28:3053\u201365.","journal-title":"Clin Cancer Res"},{"key":"1734_CR325","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","volume":"26","author":"JM Versluis","year":"2020","unstructured":"Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med. 2020;26:475\u201384.","journal-title":"Nat Med."},{"key":"1734_CR326","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41:1551\u201366.","journal-title":"Cancer Cell."},{"key":"1734_CR327","doi-asserted-by":"publisher","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0182.","journal-title":"Science"},{"key":"1734_CR328","doi-asserted-by":"crossref","unstructured":"Santo V, Elkrief A, Concannon K, Di Federico A, Gandhi MM, Pecci F, et al. Differential predictive impact of PD-L1 expression on immunotherapy outcomes and immunophenotype in squamous versus non-squamous NSCLC. J Clin Oncol. 2025;43:8562.","DOI":"10.1200\/JCO.2025.43.16_suppl.8562"},{"key":"1734_CR329","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.11181","volume":"6","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal C, Ben-Shachar R, Gao Y, Hyun SW, Rivers Z, Epstein C, et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw Open. 2023;6: e2311181.","journal-title":"JAMA Netw Open"},{"key":"1734_CR330","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","volume":"17","author":"M Mino-Kenudson","year":"2022","unstructured":"Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, et al. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2022;17:1335\u201354.","journal-title":"J Thorac Oncol"},{"key":"1734_CR331","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"},{"key":"1734_CR332","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598\u2013608.","journal-title":"Mol Cancer Ther"},{"key":"1734_CR333","doi-asserted-by":"publisher","unstructured":"Johannet P, Rousseau B, Aghajanian C, Foote MB, Diaz LA Jr. Therapeutic targeting of mismatch repair-deficient cancers. Nat Rev Clin Oncol. 2025. https:\/\/doi.org\/10.1038\/s41571-025-01054-6. Epub ahead of print.","DOI":"10.1038\/s41571-025-01054-6"},{"key":"1734_CR334","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","volume":"22","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini M, Manca P, Nasca V, Sciortino C, Ghelardi F, Seligmann JF, et al. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat Rev Clin Oncol. 2025;22:385\u2013407.","journal-title":"Nat Rev Clin Oncol"},{"key":"1734_CR335","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"1734_CR336","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"1734_CR337","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jamaoncol.2019.2311","volume":"5","author":"JS Lee","year":"2019","unstructured":"Lee JS, Ruppin E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol. 2019;5:1614\u20138.","journal-title":"JAMA Oncol"},{"key":"1734_CR338","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br J Cancer"},{"key":"1734_CR339","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.cpt.2022.12.002","volume":"1","author":"H Ahmed","year":"2022","unstructured":"Ahmed H, Mahmud AR, Siddiquee MF, Shahriar A, Biswas P, Shimul MEK, et al. Role of T cells in cancer immunotherapy: Opportunities and challenges. Cancer Pathog Ther. 2022;1:116\u201326.","journal-title":"Cancer Pathog Ther."},{"key":"1734_CR340","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41416-022-02119-4","volume":"128","author":"K Brummel","year":"2023","unstructured":"Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128:451\u20138.","journal-title":"Br J Cancer"},{"key":"1734_CR341","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.jtho.2021.07.027","volume":"16","author":"M Shirasawa","year":"2021","unstructured":"Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, et al. Differential immune-related microenvironment determines programmed cell death protein-1\/programmed death-ligand 1 blockade efficacy in patients with advanced NSCLC. J Thorac Oncol. 2021;16:2078\u201390.","journal-title":"J Thorac Oncol"},{"key":"1734_CR342","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jtho.2021.04.016","volume":"16","author":"J Yeong","year":"2021","unstructured":"Yeong J, Suteja L, Simoni Y, Lau KW, Tan AC, Li HH, et al. Intratumoral CD39(+)CD8(+) T cells predict response to programmed cell death protein-1 or programmed death ligand-1 blockade in patients with NSCLC. J Thorac Oncol. 2021;16:1349\u201358.","journal-title":"J Thorac Oncol"},{"key":"1734_CR343","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","volume":"24","author":"AM Holder","year":"2024","unstructured":"Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24:498\u2013512.","journal-title":"Nat Rev Cancer"},{"key":"1734_CR344","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1007\/s00262-023-03485-5","volume":"72","author":"L Huang","year":"2023","unstructured":"Huang L, Lou N, Xie T, Tang L, Han X, Shi Y. Identification of an antigen-presenting cells\/T\/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing. Cancer Immunol Immunother. 2023;72:3259\u201377.","journal-title":"Cancer Immunol Immunother."},{"key":"1734_CR345","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s00262-023-03428-0","volume":"72","author":"S Wang","year":"2023","unstructured":"Wang S, Fan G, Li L, He Y, Lou N, Xie T, et al. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC. Cancer Immunol, Immunother. 2023;72:2423\u201342.","journal-title":"Cancer Immunol, Immunother."},{"key":"1734_CR346","doi-asserted-by":"crossref","unstructured":"Xie T, Fan G, Tang L, Xing P, Shi Y. Artificial neural network systems to predict the response to sintilimab in squamous-cell non-small-cell lung cancer based on data of ORIENT-3 study. Cancer Immunol Immunother. 2024;74:29.","DOI":"10.1007\/s00262-024-03886-0"},{"key":"1734_CR347","doi-asserted-by":"crossref","unstructured":"Lou N, Yang M, Xie Z, Gao R, Zhang L, Tang L, et al. JAK3 A573V and JAK3 M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3\/PD-L1 pathway. J Immunother Cancer. 2025;13:e010783.","DOI":"10.1136\/jitc-2024-010783"},{"key":"1734_CR348","doi-asserted-by":"publisher","first-page":"6399","DOI":"10.7150\/thno.45816","volume":"10","author":"Q Tan","year":"2020","unstructured":"Tan Q, Wang D, Yang J, Xing P, Yang S, Li Y, et al. Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. Theranostics. 2020;10:6399\u2013410.","journal-title":"Theranostics."},{"key":"1734_CR349","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102731","volume":"54","author":"Y Shi","year":"2020","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. EBioMedicine. 2020;54: 102731.","journal-title":"EBioMedicine"},{"key":"1734_CR350","doi-asserted-by":"crossref","unstructured":"Dai L, Tan Q, Li L, Lou N, Zheng C, Yang J, et al. High-Throughput antigen microarray identifies longitudinal prognostic autoantibody for chemoimmunotherapy in advanced non-small cell lung cancer. Mol Cell Proteomics. 2024;23:100749.","DOI":"10.1016\/j.mcpro.2024.100749"},{"key":"1734_CR351","doi-asserted-by":"crossref","unstructured":"Tan Q, Gao R, Zhang X, Yang J, Xing P, Yang S, et al. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients. Cancer Immunol, Immunother. 2024;73:47.","DOI":"10.1007\/s00262-024-03631-7"},{"key":"1734_CR352","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4552","volume":"371","author":"GD Sepich-Poore","year":"2021","unstructured":"Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, Knight R. The microbiome and human cancer. Science. 2021;371: eabc4552.","journal-title":"Science"},{"key":"1734_CR353","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","volume":"39","author":"N Cullin","year":"2021","unstructured":"Cullin N, Azevedo Antunes C, Straussman R, Stein-Thoeringer CK, Elinav E. Microbiome and cancer. Cancer Cell. 2021;39:1317\u201341.","journal-title":"Cancer Cell"},{"key":"1734_CR354","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","volume":"25","author":"BA Helmink","year":"2019","unstructured":"Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25:377\u201388.","journal-title":"Nat Med"},{"key":"1734_CR355","doi-asserted-by":"publisher","first-page":"e14151","DOI":"10.1200\/JCO.2019.37.15_suppl.e14151","volume":"37","author":"B Thapa","year":"2019","unstructured":"Thapa B, Roopkumar J, Kim AS, Gervaso L, Patil PD, Calabrese C, et al. Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI). J Clin Oncol. 2019;37:e14151\u2013e14151.","journal-title":"J Clin Oncol"},{"key":"1734_CR356","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","volume":"5","author":"KPM Suijkerbuijk","year":"2024","unstructured":"Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM. Clinical and translational attributes of immune-related adverse events. Nat Cancer. 2024;5:557\u201371.","journal-title":"Nat Cancer"},{"key":"1734_CR357","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.34678","volume":"129","author":"R Maniar","year":"2023","unstructured":"Maniar R, Loehrer PJ. Understanding the landscape of immunotherapy in thymic epithelial tumors. Cancer. 2023;129:1162\u201372.","journal-title":"Cancer"},{"key":"1734_CR358","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162\u201370.","journal-title":"J Clin Oncol"},{"key":"1734_CR359","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347\u201355.","journal-title":"Lancet Oncol"},{"key":"1734_CR360","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0723-9","volume":"7","author":"A Rajan","year":"2019","unstructured":"Rajan A, Heery CR, Thomas A, Mammen AL, Perry S, O\u2019Sullivan Coyne G, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7: 269.","journal-title":"J Immunother Cancer"},{"key":"1734_CR361","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377\u201385.","journal-title":"Ann Oncol"},{"key":"1734_CR362","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.","journal-title":"Nat Rev Dis Primers"},{"key":"1734_CR363","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"1734_CR364","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","volume":"152","author":"M Salzmann","year":"2021","unstructured":"Salzmann M, Tosev G, Heck M, Schadendorf D, Maatouk I, Enk AH, et al. Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study. Eur J Cancer. 2021;152:41\u20138.","journal-title":"Eur J Cancer"},{"key":"1734_CR365","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100276","volume":"6","author":"M Garutti","year":"2021","unstructured":"Garutti M, Lambertini M, Puglisi F. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open. 2021;6: 100276.","journal-title":"ESMO Open"},{"key":"1734_CR366","doi-asserted-by":"publisher","first-page":"e006500","DOI":"10.1136\/jitc-2022-006500","volume":"11","author":"CC Barron","year":"2023","unstructured":"Barron CC, Stefanova I, Cha Y, Elsolh K, Zereshkian A, Gaafour N, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11:e006500.","journal-title":"J Immunother Cancer"},{"key":"1734_CR367","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40:3430\u20138.","journal-title":"J Clin Oncol"},{"key":"1734_CR368","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142:2299\u2013311.","journal-title":"Circulation"},{"key":"1734_CR369","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol."},{"key":"1734_CR370","doi-asserted-by":"crossref","unstructured":"Martin E, Mathevet F, Dauxois JY, Porcher R, Delord JP. Assessment of treatment effects and long-term benefits in immune checkpoint inhibitor trials using the flexible parametric cure model: a systematic review. JAMA Netw Open. 2021;4:e2139573.","DOI":"10.1001\/jamanetworkopen.2021.39573"},{"key":"1734_CR371","doi-asserted-by":"crossref","unstructured":"Huang L, Zhu H, Dai L, Feng Y, Chen X, Xie Z, et al. Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer. Cancer Immunol Immunother. 2025;74:219.","DOI":"10.1007\/s00262-025-04022-2"},{"key":"1734_CR372","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","volume":"31","author":"SK Yoo","year":"2025","unstructured":"Yoo SK, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat Med. 2025;31:869\u201380.","journal-title":"Nat Med."},{"key":"1734_CR373","doi-asserted-by":"publisher","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","volume":"10","author":"SJ Rodig","year":"2018","unstructured":"Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10:eaar3342.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1734_CR374","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","volume":"29","author":"N Jacquelot","year":"2019","unstructured":"Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, et al. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019;29(10):846\u201361.","journal-title":"Cell Res"},{"key":"1734_CR375","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7:188\u2013201.","journal-title":"Cancer Discov"},{"key":"1734_CR376","doi-asserted-by":"crossref","unstructured":"Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359:770\u20135.","DOI":"10.1126\/science.aao1710"},{"key":"1734_CR377","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 2021;11:874\u201399.","journal-title":"Cancer Discov"},{"key":"1734_CR378","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374.","journal-title":"Annu Rev Immunol"},{"key":"1734_CR379","doi-asserted-by":"crossref","unstructured":"Gui L, Xie Z, Zhang W, Chen X, Liu S, Wang X, et al. Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase II trial. ESMO Open. 2025;10:105505.","DOI":"10.1016\/j.esmoop.2025.105505"},{"key":"1734_CR380","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","volume":"8","author":"KB Pointer","year":"2022","unstructured":"Pointer KB, Pitroda SP, Weichselbaum RR. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022;8:9\u201320.","journal-title":"Trends Cancer."},{"key":"1734_CR381","doi-asserted-by":"crossref","unstructured":"Zhang C, Chen J, Wu H, Wang J, Gao L, Zhao J, et al. Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial. Cancer Pathog Ther. 2024;2:268\u201375.","DOI":"10.1016\/j.cpt.2024.02.001"},{"key":"1734_CR382","doi-asserted-by":"crossref","unstructured":"Tapia-Galisteo A, \u00c1lvarez-Vallina L, Sanz L. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023;16:83.","DOI":"10.1186\/s13045-023-01482-w"},{"key":"1734_CR383","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler ME, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21:539\u201360.","journal-title":"Nat Rev Clin Oncol."},{"key":"1734_CR384","doi-asserted-by":"crossref","unstructured":"Yang J, Yu Y, Ren X, et al. 59O A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent\/refractory (r\/r) lymphoma. Ann Oncol. 2024;35:S1427.","DOI":"10.1016\/j.annonc.2024.10.080"},{"key":"1734_CR385","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-024-01646-2","volume":"17","author":"J Yang","year":"2024","unstructured":"Yang J, Song Y, Zhou K, Li Z, Zhang M, Jing H, et al. Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP\u03b1, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1\/2 study. J Hematol Oncol. 2024;17:123.","journal-title":"J Hematol Oncol"},{"issue":"29","key":"1734_CR386","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"15","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res. 2023;15(29):1835\u201354.","journal-title":"Clin Cancer Res"},{"key":"1734_CR387","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: the evolution of CAR-T cell therapy. Mol Ther. 2025;33:2123\u201340.","journal-title":"Mol Ther"},{"key":"1734_CR388","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101516","volume":"5","author":"J Ingels","year":"2024","unstructured":"Ingels J, De Cock L, Stevens D, Mayer RL, Th\u00e9ry F, Sanchez GS, et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep Med. 2024;5: 101516.","journal-title":"Cell Rep Med"},{"key":"1734_CR389","doi-asserted-by":"crossref","unstructured":"Yadegar A, Bar-Yoseph H, Monaghan TM, Pakpour S, Severino A, Kuijper EJ, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev. 2024;37:e0006022.","DOI":"10.1128\/cmr.00060-22"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01734-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01734-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:11:54Z","timestamp":1764267114000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01734-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":389,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01734-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}